The latest medicinal products to receive Marketing Authorization from the BDA and expand Tchaikapharma’s rich and diverse portfolio are:

– Tamaira Plus 5 mg/5 mg/12.5 mg; 5 mg/5 mg/25 mg; 10 mg/5 mg/25 mg hard capsules (with APIs ramipril, amlodipine and hydrochlorothiazide).

The medicinal product is indicated for the treatment of high blood pressure (hypertension) in adult patients adequately controlled with the individual products given concurrently at the same
dose level as in the combination, but as separate tablets.

The medicinal product is subject to medical prescription.

ATC code: C09BX03

– Rivaroxaban-Chaikapharma 10 mg; 15 mg; 20 mg film-coated tablets (rivaroxaban).

The medicinal product belongs to a group of medicines called antithrombotic agents. By its action, it blocks one factor of blood clotting (factor Xa) and thus reduces the ability of blood to form clots.

Rivaroxaban 10 mg – is used to prevent clots forming in veins after hip or knee replacement surgery. It is used to treat clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent their re-formation.

Rivaroxaban 15 mg; 20 mg – is used to prevent clots from forming in the brain (stroke) and in other blood vessels of the body if the patient has one type of cardiac arrhythmia called non-valvular atrial fibrillation. It is used to treat clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent them from forming again.

The medicinal product is subject to medical prescription.

ATC code: B01AF01